Patient characteristics
Patient . | Age, y . | Sex . | Diagnosis . | Donor . | Regimen . | Acute GVHD grade . | Peak EBV, copies per mL* . | PTLD . |
---|---|---|---|---|---|---|---|---|
High EBV | ||||||||
1 | 34 | M | AML | MUD | Cy TBI C | II+ | 4.35 × 106 | + |
2 | 57 | M | AML | MUD | FMC | II+ | 2.16 × 105 | |
3 | 57 | M | AML | MUD | FMC | I | 1.60 × 105 | |
4 | 55 | M | AML | MUD | FMC | II+ | 3.31 × 104 | |
5 | 64 | M | MDS | MUD | FMC | II+ | 1.81 × 106 | + |
6 | 51 | M | AML | MUD | FMC | I | 1.41 × 105 | |
7 | 61 | M | AML | MUD | FMC | 9.73 × 104 | ||
8 | 48 | M | HL | MUD | FMC | II+ | 2.69 × 104 | |
9 | 57 | F | CLL | MUD | FMC | II+ | 1.54 × 106 | |
10 | 57 | M | AML | Sibling | FMC | I | 9.49 × 104 | + |
11 | 67 | F | MDS | MUD | FMC | 1.67 × 106 | ||
12 | 61 | M | AML | MUD | FMC | II+ | 5.36 × 105 | |
13 | 50 | F | AML | Sibling | FMC | I | 2.50 × 105 | |
No/low EBV | ||||||||
14 | 55 | M | AML | MUD | FMC | 9.67 × 102 | ||
15 | 61 | M | AML | MUD | FMC | 1.80 × 103 | ||
16 | 65 | M | AML | Sibling | FMC | II+ | 3.20 × 103 | |
17 | 51 | F | ALL | Sibling | FMC | I | 3.65 × 103 | |
18 | 57 | M | MDS | MUD | FMC | I | <5 × 102 | |
19 | 54 | M | ALL | MUD | FMC | I | 3.29 × 103 | |
20 | 54 | F | HL | Sibling | FMC | II+ | 4.24 × 103 | |
21 | 58 | M | T-PLL | Sibling | FMC | 3.80 × 103 | ||
22 | 62 | M | AML | MUD | FMC | 1.34 × 103 | ||
23 | 64 | M | AML | MUD | FMC | I | 1.23 × 103 | |
24 | 70 | F | AML | MUD | FMC | <5 × 102 | ||
25 | 66 | M | AML | MUD | FMC | II+ | 1.37 × 103 | |
26 | 53 | M | AML | Sibling | FMC | <5 × 102 | ||
27 | 61 | M | MDS | Sibling | FMC | 5.50 × 103 | ||
28 | 44 | M | MF | MUD | FMC | <5 × 102 | ||
29 | 47 | F | AML | MUD | FMC | I | <5 × 102 |
Patient . | Age, y . | Sex . | Diagnosis . | Donor . | Regimen . | Acute GVHD grade . | Peak EBV, copies per mL* . | PTLD . |
---|---|---|---|---|---|---|---|---|
High EBV | ||||||||
1 | 34 | M | AML | MUD | Cy TBI C | II+ | 4.35 × 106 | + |
2 | 57 | M | AML | MUD | FMC | II+ | 2.16 × 105 | |
3 | 57 | M | AML | MUD | FMC | I | 1.60 × 105 | |
4 | 55 | M | AML | MUD | FMC | II+ | 3.31 × 104 | |
5 | 64 | M | MDS | MUD | FMC | II+ | 1.81 × 106 | + |
6 | 51 | M | AML | MUD | FMC | I | 1.41 × 105 | |
7 | 61 | M | AML | MUD | FMC | 9.73 × 104 | ||
8 | 48 | M | HL | MUD | FMC | II+ | 2.69 × 104 | |
9 | 57 | F | CLL | MUD | FMC | II+ | 1.54 × 106 | |
10 | 57 | M | AML | Sibling | FMC | I | 9.49 × 104 | + |
11 | 67 | F | MDS | MUD | FMC | 1.67 × 106 | ||
12 | 61 | M | AML | MUD | FMC | II+ | 5.36 × 105 | |
13 | 50 | F | AML | Sibling | FMC | I | 2.50 × 105 | |
No/low EBV | ||||||||
14 | 55 | M | AML | MUD | FMC | 9.67 × 102 | ||
15 | 61 | M | AML | MUD | FMC | 1.80 × 103 | ||
16 | 65 | M | AML | Sibling | FMC | II+ | 3.20 × 103 | |
17 | 51 | F | ALL | Sibling | FMC | I | 3.65 × 103 | |
18 | 57 | M | MDS | MUD | FMC | I | <5 × 102 | |
19 | 54 | M | ALL | MUD | FMC | I | 3.29 × 103 | |
20 | 54 | F | HL | Sibling | FMC | II+ | 4.24 × 103 | |
21 | 58 | M | T-PLL | Sibling | FMC | 3.80 × 103 | ||
22 | 62 | M | AML | MUD | FMC | 1.34 × 103 | ||
23 | 64 | M | AML | MUD | FMC | I | 1.23 × 103 | |
24 | 70 | F | AML | MUD | FMC | <5 × 102 | ||
25 | 66 | M | AML | MUD | FMC | II+ | 1.37 × 103 | |
26 | 53 | M | AML | Sibling | FMC | <5 × 102 | ||
27 | 61 | M | MDS | Sibling | FMC | 5.50 × 103 | ||
28 | 44 | M | MF | MUD | FMC | <5 × 102 | ||
29 | 47 | F | AML | MUD | FMC | I | <5 × 102 |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; C, Campath; CLL, chronic lymphocytic leukemia; Cy, cyclophosphamide; F, female; FMC, fludarabine, melphalan, and Campath; HL, Hodgkin lymphoma; M, male; MDS, myelodysplastic syndrome; MF, myelofibrosis; MUD, matched unrelated donor; T-PLL, T-cell prolymphocytic leukemia; TBI, total body irradiation.
Clinical EBV load measured as EBV DNA copies per mL whole blood.